WO2009111727A4 - Compositions comprising ghrh and gnrh and methods of using the same - Google Patents
Compositions comprising ghrh and gnrh and methods of using the same Download PDFInfo
- Publication number
- WO2009111727A4 WO2009111727A4 PCT/US2009/036379 US2009036379W WO2009111727A4 WO 2009111727 A4 WO2009111727 A4 WO 2009111727A4 US 2009036379 W US2009036379 W US 2009036379W WO 2009111727 A4 WO2009111727 A4 WO 2009111727A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- encodes
- nucleotide sequence
- gnrh
- ghrh
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Compositions and kits comprising a nucleotide sequence that encodes GHRH and a nucleotide sequence that encodes GnRH and compositions and kits comprising a GHRH protein and GnRH protein are disclosed. Use of such compositions and kits in methods of enhancing fertility in mammals comprising the step of administering said compositions to the mammal are disclosed.
Claims
1. Λ pharmaceutical composition formulated for administration to a mammal in order to introduce to a cell of the mammal a GHRH product and a GnRH product, wherein the GHRH product comprises a nucleotide sequence that encodes GHRH or a GHRH protein, and the GnRH product comprises a nucleotide sequence that encodes GnRH or a GnRH protein.
2. The composition according to claim 1 , wherein the nucleotide sequence that encodes GHRH and the nucleotide sequence that encodes GnRH, independently, are a horse sequence, dog sequence, cat sequence, pig sequence, cow sequence, sheep sequence, goat sequence, or primate sequence.
3. The composition according to any one of claims 1 -2, wherein the nucleotide sequence that encodes GHRH and the nucleotide sequence that encodes GnRH are wild-type sequences.
4. The composition according to claim 3, wherein the nucleotide sequence that encodes GHRH and the nucleotide sequence that encodes GnRH are codon optimized sequences.
5. The composition according to claim 4, wherein the nucleotide sequence that encodes GHRH encodes a GHRH having an amino acid sequence as set forth in SEQ ID NO: 5.
6. The composition according to claim S, wherein the nucleotide sequence encodes GnRH encodes a GnRH having an amino acid sequence as set forth in SEQ ID NO: 3.
7. The composition according to claim 6, comprising a plasmid that comprises the nucleotide sequence that encodes GHRH and the nucleotide sequence that encodes GnRH, or a mixture of a first plasmid that comprises the nucleotide sequence that encodes GHRH and a second plasmid that comprises the nucleotide sequence that encodes GnRH.
i
8. The composition according to claim 7, wherein nucleotide sequence that encodes OHRH is aplasmid having a nucleotide sequence as set forth as SEQ ID NO: 4 and the nucleotide sequence that encodes GDRH is a plasmid having a nucleotide sequence as that set forth as SEQ ID NO: 1.
9. The composition according to claim 7, comprising a viral vector that comprises the nucleotide sequence that encodes GHRH and the nucleotide sequence that encodes GnRH, or a mixture of a first viral vector that comprises the nucleotide sequence that encodes GHRH and a second viral vector that comprises the nucleotide sequence that encodes GnRH.
10. The composition according to claim 9, comprising a viral vector selected from the group consisting of: adenovirus, SV40 virus, adeno-associated virus, vaccinia virus, pox virus, retrovirus, lentivirus, and combinations thereof.
11. A kit comprising a first container comprising a nucleotide sequence that encodes GHRH or GHRH protein, and a second container comprising a nucleotide sequence that encodes GnRH or GoRH protein.
12. The kit according to claim 11 , wherein the nucleotide sequence that encodes GHRH encodes an amino acid sequence as set forth in SEQ ID NO: S and the nucleotide sequence that encodes GnRH encodes an amino acid sequence as set forth in SEQ ID NO: 3.
13. The kid according to any one of claims 11-12, wherein the nucleotide sequence that encodes GHRH has a nucleotide sequence as set forth as SEQ ID NO: 4 and the nucleotide sequence that encodes GnRH has a nucleotide sequence as that set forth as SEQ ID NO: 1.
14. A method of enhancing fertility in mammals comprising the step of administering to said mammal a pharmaceutical composition, comprising a a nucleotide sequence that encodes GHRH or GHRH protein, and a nucleotide sequence that encodes GnRH or GnRH protein.
15. The method according to claim 14 comprising the step of administering to said mammal a pharmaceutical composition comprising a nucleotide sequence that encodes GHRH and a nucleotide sequence that encodes GnRH.
16. The method according to any one of claims 14-15, comprising the step of administering to said mammal a pharmaceutical composition comprising a nucleotide sequence that encodes GHRH and GnRH.
17. The method according to claim 16, wherein the nucleotide sequence that encodes GHRH and the nucleotide sequence that encodes GnRH, independently, is a horse sequence, dog sequence, cat sequence, pig sequence, cow sequence, sheep sequence, goat sequence, or primate sequence.
18. The method according to claim 17, wherein the nucleotide sequence that encodes GHRH and the nucleotide sequence that encodes GnRH are wild-type sequences.
19. The method according to claim 18, wherein the nucleotide sequence that encodes GHRH and the nucleotide sequence that encodes GnRH are codon optimized sequences.
20. The method according to claim 19, comprising the step of administering to said mammal a plasmid that comprises the nucleotide sequence that encodes GHRH and the nucleotide sequence that encodes GnRH9 or a mixture of a first plasmid that comprises the nucleotide sequence that encodes GHRH and a second plasmid that comprises the nucleotide sequence that encodes GnRH.
21. The method according to claim 20, wherein the nucleotide sequence that encodes GHRH encodes an amino acid sequence as that set forth in SEQ ID NO: 5, and the nucleotide sequence that encodes GnRH encodes an amino acid sequence as that set forth in SEQ ID NO: 3.
22. The method according to claim 20, wherein the nucleotide sequence that encodes GHRH is a plasmid having a nucleotide sequence as that set forth in SEQ ID NO: 4 and the nucleotide sequence that encodes GnRH is a plasmid having a nucleotide sequence as that set forth in SEQ ID NO: 1.
23. The method according to claim 20, wherein the step of administering the pharmaceutical composition comprises injecting intramuscular, injecting intradermally, injecting intravenously, or delivering transdermally.
24. The method according to claim 23, further comprising the step of electroporating tissue of the mammal after the step of administering the pharmaceutical composition.
25. The method according to claim 24, comprising electroporating the tissue after tissue of the mammal using constant current.
26. The method according to claim 19, comprising the step of administering to said mammal a viral vector that comprises the nucleotide sequence that encodes GHRH and the nucleotide sequence that encodes GnRH, or a mixture of a first viral vector that comprises the nucleotide sequence that encodes GHRH and a second viral vector that comprises the nucleotide sequence that encodes GnRH.
27. The method according to claim 20, wherein the mammal is selected from the group consisting of: horses, dogs, cats, pigs, cows, sheep, goats, and primates.
28. The method according to claim 27, wherein the mammal exhibits enhanced fertility over an untreated mammal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/920,545 US8962818B2 (en) | 2008-03-06 | 2009-03-06 | Compositions comprising GHRH and GnRH and methods of using the same |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3447308P | 2008-03-06 | 2008-03-06 | |
| US61/034,473 | 2008-03-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009111727A1 WO2009111727A1 (en) | 2009-09-11 |
| WO2009111727A4 true WO2009111727A4 (en) | 2009-10-22 |
Family
ID=41056381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2009/036379 Ceased WO2009111727A1 (en) | 2008-03-06 | 2009-03-06 | Compositions comprising ghrh and gnrh and methods of using the same |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US8962818B2 (en) |
| WO (1) | WO2009111727A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8993316B2 (en) | 2011-11-16 | 2015-03-31 | Brian P. Hanley | Methods and compositions for gene therapy and GHRH therapy |
| MX2020008147A (en) * | 2018-02-02 | 2020-10-28 | Acerus Biopharma Inc | Methods of testosterone therapy. |
| WO2019213624A1 (en) * | 2018-05-04 | 2019-11-07 | The Regents Of The University Of California | Spiked primers for enrichment of pathogen nucleic acids among background of nucleic acids |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387695B1 (en) * | 1997-12-23 | 2002-05-14 | Merck & Co., Inc. | DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof |
| US7517863B2 (en) * | 2004-01-20 | 2009-04-14 | Vgx Pharmaceuticals, Inc. | Enhanced secretion/retention of growth hormone releasing hormone (GHRH) from muscle cells by species-specific signal peptide |
-
2009
- 2009-03-06 US US12/920,545 patent/US8962818B2/en active Active
- 2009-03-06 WO PCT/US2009/036379 patent/WO2009111727A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US8962818B2 (en) | 2015-02-24 |
| US20110034544A1 (en) | 2011-02-10 |
| WO2009111727A1 (en) | 2009-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210363193A1 (en) | Modified aav capsid polypeptides for treatment of muscular diseases | |
| JP6665269B2 (en) | Non-human animal having humanized signal regulatory protein gene | |
| US20250346664A1 (en) | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) | |
| Parmentier et al. | Candidate gene markers associated with somatotropic axis and milk selection☆ | |
| JP6884860B2 (en) | Non-human animal with engineered immunoglobulin lambda light chain locus | |
| JP2020198894A (en) | Non-human animals having hexanucleotide repeat expansion in c9orf72 locus | |
| ES2700972T3 (en) | Non-human animals that have a humanized B cell activating factor gene | |
| US12448636B2 (en) | High-efficiency reconstitution of RNA molecules | |
| JP2009532053A (en) | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo | |
| US20140234322A1 (en) | Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury | |
| EP4484562A2 (en) | Non-human animals comprising a humanized asgr1 locus | |
| Bu et al. | Identification of a novel functional corticotropin-releasing hormone (CRH2) in chickens and its roles in stimulating pituitary TSHβ expression and ACTH secretion | |
| TWI331156B (en) | Protease resistant ti-growth hormone releasing hormone | |
| WO2009111727A4 (en) | Compositions comprising ghrh and gnrh and methods of using the same | |
| Lugo et al. | Recombinant novel pituitary adenylate cyclase-activating polypeptide from African catfish (Clarias gariepinus) authenticates its biological function as a growth-promoting factor in low vertebrates | |
| CN109890404A (en) | Visual function regenerating agent or visual function lowering preventive agent | |
| Carpio et al. | Regulation of body mass growth through activin type IIB receptor in teleost fish | |
| US20040038918A1 (en) | Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy | |
| US20250320509A1 (en) | Compositions and methods for treating wilson's disease | |
| Tooney et al. | TACHYKININ NK [sub1] AND NK [sub3] RECEPTORS IN THE PREFRONTAL CORTEX OF THE HUMAN BRAIN. | |
| CN1575301A (en) | Administration of nucleic acid sequence to female animal | |
| US20240139253A1 (en) | Post-Natal Transplantation Of Factor VIII-Expressing Cells For Treatment of Hemophilia | |
| US6531305B1 (en) | Sperm associated protein kinase polypeptides, corresponding nucleic acids, and methods of use | |
| Draghia-Akli et al. | Plasmid-based expression technology using growth hormone releasing hormone: a novel method for physiologically stimulating long-term growth hormone secretion | |
| Vilalta et al. | Rabbit EPO gene and cDNA: Expression of rabbit EPO after intramuscular injection of pDNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09717140 Country of ref document: EP Kind code of ref document: A1 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12920545 Country of ref document: US |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09717140 Country of ref document: EP Kind code of ref document: A1 |